Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 10/20 | 0.47 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9033440 | 0.86 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL3784713 | 0.86 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL27224005 | 0.86 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL9033443 | 0.86 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL9603360 | 0.86 | AGTR2 (0.59) | AGTR2BDKRB2MMP9 | |
| SCHEMBL22091651 | 0.86 | AGTR2 (0.47) | AGTR2BDKRB2MMP9 | |
| SCHEMBL17099064 | 0.83 | AGTR2 (0.44) | AGTR2BDKRB2MMP9NAAA | |
| SCHEMBL4301232 | 0.82 | NAAA (0.44) | AGTR2BDKRB2MMP9NAAA | |
| SCHEMBL25257331 | 0.80 | NAAA (0.44) | BDKRB2IDO1NAAASIGMAR1 | |
| SCHEMBL5754489 | 0.76 | AGTR2 (0.57) | AGTR2BDKRB2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | MSD ITALIA S.R.L. (IT) | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266897-A1 | HCV NS3 Protease Inhibitors | HAVCR2, GTF3C3, CTSC | AGTR2 3399/4885BDKRB2 3878/4885IDO1 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.